<DOC>
	<DOCNO>NCT00593827</DOCNO>
	<brief_summary>The purpose study determine effect weekly regimen ixabepilone dose compare every 3 week dose regimen participant metastatic breast cancer .</brief_summary>
	<brief_title>Phase II Trial Weekly Every 3-week Ixabepilone Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Has MBC measurable RECIST nonmeasurable disease serum CA27.29 ( CA15.3 ) ≥ 50 Has Human Epidermal Growth Factor Receptor 2 ( HER2 ) negative breast cancer Prior chemotherapy permit limit number prior regimen Two week elapse since last chemotherapy radiation treatment Has Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 02 Is female , ≥ 18 yrs age Protocol define appropriate laboratory value Negative pregnancy test within 7 calendar day prior registration Has sign patient inform consent Had prior treatment ixabepilone epothilones Has HER2+ disease Has know , prior , severe ( National Cancer Institute Common Terminology Criteria Adverse Events [ NCI CTCAE ] Grade 34 ) history hypersensitivity reaction drug formulate Cremophor ® EL ( polyoxyethylated castor oil ) Is receive concurrent immunotherapy , hormonal therapy radiation therapy Is receive concurrent investigational therapy receive therapy within past 30 day Has peripheral neuropathy &gt; Grade 1 Has evidence central nervous system ( CNS ) involvement require radiation steroid treatment . Participants stable brain metastasis steroids least 2 week eligible Is pregnant breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>